This latest set of changes has the potential to streamline the diagnostic process in people with suspected MS, increasing the number of patients diagnosed at the time of disease onset rather than requiring follow-up MRI scans, or a second clinical attack. 4 However, nearly half of people with MS are unable to be diagnosed at the time of presentation, even when applying the most up-to-date revisions to the McDonald criteria. 4 It seems likely that there will be further changes to the diagnostic criteria for MS in the future as new evidence becomes available. For example, a recent study found that including optic nerve lesions (detected clinically and/or with visual evoked potential testing) 3 However, despite considerable effort over the last 10 years or more, DIR is not routinely available outside highly specialist centres.
Neurologists diagnosing and treating MS are fortunate that they have a robust set of diagnostic criteria that allow for an early and accurate diagnosis of MS. 9 These criteria are likely to undergo further revision in the future as new evidence becomes available. However, the active consideration and exclusion of other disorders, a caveat that has been at the heart of diagnostic criteria for MS over the last 50 years, will almost certainly remain. This requires careful integration of the patient's symptoms and signs, focussed investigation and clinical acumen, not new diagnostic criteria to distinguish MS from other conditions.
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The history of diagnostic criteria for multiple sclerosis (MS) dates back more than 50 years ago when the Schumacher et al. 1 panel outlined a conceptual framework of the disease with the intent to generate a common definition for MS research. This framework has undergone little changes over time and, specifically for attack onset MS, still rests on evidence for multiple (⩾2) lesions of the central nervous system (CNS) in different locations (dissemination in space, DIS) which have occurred at different times (dissemination in time, DIT) in the absence of a better explanation for their etiology, that is, after other differentials have been excluded. 2 What has changed, however, is the way how such evidence can be generated, that is, depiction of MS lesions by magnetic resonance imaging (MRI) has gained much weight, and the use of diagnostic criteria for MS has moved from research into clinical practice. The introduction of diseasemodifying treatments also makes a fast diagnosis desirable. All this has created a situation where diagnostic scrutiny is obviously not always sufficient and the present discussion attempts to clarify how we should best proceed.
As outlined by the proponent of the McDonald criteria, the 2017 revisions have attempted to further improve on their applicability. 3 The separation between symptomatic and asymptomatic MRI lesions was abandoned in view of evidence that this would not compromise the delicate balance between sensitivity and specificity. Likewise, the reconsideration of cerebrospinal fluid (CSF)-specific oligoclonal bands was felt to add both to sensitivity and specificity. Well aware of the etiologic uncertainties around both MRI lesions and oligoclonal bands, special emphasis was put on the fact that the diagnostic criteria can only be applied in the appropriate clinical setting, that is, to patients with clinical findings compatible with MS and important definitions and considerations when using these criteria have been reiterated and strengthened. It is hoped that these clarifications are taken on.
That this still may not be the case to a sufficient extent is a valid concern and the call for more research efforts into the diagnosis of MS is well taken. 4 If we need a separate set of criteria for differential diagnosis is debateable, however. There actually exist already numerous recommendations regarding the appropriate clinical and imaging assessment of patients suspected to suffer from MS 5, 6 and new ones are added. 7, 8 Certainly it would be ideal to find a marker which is absolutely specific for MS but expectations for success should not be too high. Admittedly, it is also unlikely that further modifications of the McDonald criteria will make a major difference given the overall small gains achieved with the recent revision. 9,10 Thus, increased efforts should go into education and teaching of the appropriate diagnostic workup for MS and how to apply the current criteria to the right patient and in the right setting. 2 We should also not risk a potentially false diagnosis of MS just because we would like to somehow label a patient's symptoms (which is often requested) or to offer treatment. In
